Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1466)	12/23/2005 11:57:32 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

DNDN Wants to retest the resistance at the $6 level. After a 1.5M shrs over-allotment to BAC and others at $4.50/shr earlier this month. (That price was below the price that the insiders reportedly had bought earlier this year.) <g> bigcharts.marketwatch.com On Nov.29 it announced that it had reached an agreement with the FSA for an SPA to amend the design of its P 3 of PROVENGE for prostatic Ca. Before, in order to enroll patients were supposed to have a Gleason score >7 but under the SPA they will now be eligible to enroll regardless of the score, and patients with minimally symptomatic disease-related pain will be also eligible. The primary endpoint is now overall survival and progression is a secondary endpoint. DNDN has already completed 2 P3s of PROVENGE in patients with asymptomatic, metastatic, advanced prostatic Ca and it has already announced plans to submit a BLA to the FDA in 2006 to market PROVENGE for the treatment of men with asymptomatic,metastatic,androgen-independent prostatic Ca. The stock needs to close above 6.25 in order to retest its September H at 7.37 <g> bigcharts.marketwatch.com Bernard